Cite
HARVARD Citation
O'Day, S. et al. (n.d.). 398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy. Journal for immunotherapy of cancer. p. A242. [Online].